Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase II, Multicenter, Non-randomized, Single-arm, Open-label Trial of Atezolizumab in Combination of Split-doses of Gemcitabine Plus Cisplatin in Patients With Locally Advanced or Metastatic Urothelial Carcinoma

NCT04602078 is registered in ClinicalTrials.gov with Spanish Oncology Genito-Urinary Group as lead sponsor.

NCT NCT04602078
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04602078 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase II, Multicenter, Non-randomized, Single-arm, Open-label Trial of Atezolizumab in Combination of Split-doses of Gemcitabine Plus Cisplatin in Patients With Locally Advanced or Metastatic Urothelial Carcinoma
Lead sponsor
Spanish Oncology Genito-Urinary Group
Phase
Phase 2
Overall status
Completed
Start date
December 23, 2020
Completion date
February 2, 2024
Enrollment
82 (actual)
Sites
12

Conditions

As the registry lists them; a condition with its own page is linked.

locally advanced or metastatic urothelial carcinoma